{"commentary":{"count":9,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":5,"youtube":2,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03383458\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CheckMate 9DX","nct_id":"NCT03383458","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-9dx-nct03383458. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"CheckMate 9DX","arms":[{"description":null,"label":"Arm A","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B","type":"PLACEBO_COMPARATOR"}],"collaborators":["Ono Pharmaceutical Co., Ltd."],"completion_date":{"date":"2031-05-27","type":"ESTIMATED"},"conditions":["Hepatocellular Carcinoma","Liver Cancer"],"enrollment":{"count":545,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab","type":"BIOLOGICAL"},{"name":"Placebo","type":"OTHER"}],"last_update":"2026-07-31","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-05-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Recurrence-free Survival (RFS)","timeFrame":"Up to 49 months"}],"references":[],"start_date":{"date":"2018-04-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation","url":"https://clinicaltrials.gov/study/NCT03383458"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-9dx-nct03383458"}